PCN68 An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.205
https://www.valueinhealthjournal.com/article/S1098-3015(20)32461-X/fulltext
Title :
PCN68 An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32461-X&doi=10.1016/j.jval.2020.08.205
First page :
Section Title :
Open access? :
No
Section Order :
10154